{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:05:04Z","timestamp":1771322704367,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder caused by defective Fas cell surface death receptor-mediated lymphocyte apoptosis, resulting in chronic lymphadenomegaly, splenomegaly, and autoimmune cytopenias. Management of ALPS in dogs has not been reported previously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Describe treatment, therapeutic drug monitoring (TDM), and clinical and laboratory outcomes in Boerboel dogs with genetically confirmed ALPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Four affected Boerboel pups from a litter studied prospectively and 2 retrospectively identified littermates from a different litter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective case series. All 4 index puppies received prednisolone and proprietary sirolimus; 3 subsequently received generic sirolimus. Clinical response was assessed through physical examinations, CBCs, serum biochemistry profiles, and TDM. Two additional affected dogs were reviewed retrospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Initiation of proprietary sirolimus in the index litter was associated with resolution or near resolution of lymphadenomegaly and abdominal distension, improvement in hematologic variables, and decreased corticosteroid requirements. Gastrointestinal signs improved but recurred intermittently in pups 1 and 4. By 10\u00a0months of age, pups 2 and 3 achieved sustained, marked clinical improvement. Notably, pup 2 had all drugs discontinued and remained clinically well. A fourteen-month follow-up showed sustained overall clinical improvement in the index litter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Autoimmune lymphoproliferative syndrome can cause clinically relevant morbidity in dogs. Sirolimus, alone or with prednisolone, appeared effective and well tolerated, decreasing corticosteroid requirements and adverse effects. Genetic screening and management with sirolimus focused on patient comfort were beneficial. Clinical signs appeared to improve with age in some individuals, suggesting that de-escalation or discontinuation of treatment may be possible in selected cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag010","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:11:27Z","timestamp":1771261887000},"source":"Crossref","is-referenced-by-count":1,"title":["Autoimmune lymphoproliferative syndrome in Boerboel dogs: treatment, clinical outcomes and prevention"],"prefix":"10.1093","volume":"40","author":[{"given":"Linda J","family":"Tong","sequence":"first","affiliation":[{"name":"Internal Medicine, Perth Veterinary Specialists , 305 Selby St N, Osborne Park, Western Australia 6017 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijela","family":"Kocic","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, SydPath, St Vincent\u2019s Hospital, Sydney , New South Wales 2010 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Horgan","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital , 50 Missenden Rd, Camperdown, New South Wales 2050 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Malik","sequence":"additional","affiliation":[{"name":"Centre for Veterinary Education, B14, Sydney School of Veterinary Science, The University of Sydney , Sydney, New South Wales 2006 ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026021704061827800_ref1","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5858\/arpa.2018-0190-RS","article-title":"Autoimmune lymphoproliferative syndrome: an overview","volume":"144","author":"Matson","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2026021704061827800_ref2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00335-016-9668-1","article-title":"A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats","volume":"28","author":"Aberdein","year":"2017","journal-title":"Mamm Genome"},{"key":"2026021704061827800_ref3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1126\/science.7533326","article-title":"The Fas death factor","volume":"267","author":"Nagata","year":"1995","journal-title":"Science"},{"key":"2026021704061827800_ref4","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1177\/0300985815586224","article-title":"A novel and likely inherited lymphoproliferative disease in British Shorthair kittens","volume":"52","author":"Aberdein","year":"2015","journal-title":"Vet Pathol"},{"key":"2026021704061827800_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jvimsj\/aalag011","article-title":"Autoimmune lymphoproliferative syndrome in Boerboel dogs: clinicopathologic, diagnostic, and genetic characterization","author":"Tong","year":"2026","journal-title":"J Vet Intern Med"},{"key":"2026021704061827800_ref6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2015-11-685024","article-title":"Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome","volume":"128","author":"V\u00f6lkl","year":"2016","journal-title":"Blood"},{"key":"2026021704061827800_ref7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"2026021704061827800_ref8","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-21-0315","article-title":"Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a prospective, randomized trial of 324 dogs","volume":"27","author":"LeBlanc","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026021704061827800_ref9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2460\/ajvr.77.1.65","article-title":"Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs","volume":"77","author":"Larson","year":"2016","journal-title":"Am J Vet Res"},{"key":"2026021704061827800_ref10","doi-asserted-by":"publisher","first-page":"e11013","DOI":"10.1371\/journal.pone.0011013","article-title":"Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs","volume":"5","author":"Paoloni","year":"2010","journal-title":"PLoS One"},{"key":"2026021704061827800_ref11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1083-8791(03)00148-4","article-title":"Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates","volume":"9","author":"Hogan","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026021704061827800_ref12","first-page":"383","article-title":"Sirolimus in transplantation","volume":"45","author":"Stepkowski","year":"1997","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2026021704061827800_ref13","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s11357-024-01484-7","article-title":"Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project","volume":"47","author":"Coleman","year":"2025","journal-title":"GeroScience"},{"key":"2026021704061827800_ref14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bj.2021.06.005","article-title":"The genetic landscape of the FAS pathway deficiencies","volume":"44","author":"Magerus","year":"2021","journal-title":"Biom J"},{"key":"2026021704061827800_ref15","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","article-title":"Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations","volume":"123","author":"Price","year":"2014","journal-title":"Blood"},{"key":"2026021704061827800_ref16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.cdd.4401190","article-title":"Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways","volume":"10","author":"Rieux-Laucat","year":"2003","journal-title":"Cell Death Differ"},{"key":"2026021704061827800_ref17","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jpba.2010.06.030","article-title":"Quantitative determination of sirolimus in dog blood using liquid chromatography\u2013tandem mass spectrometry, and its applications to pharmacokinetic studies","volume":"53","author":"Lee","year":"2010","journal-title":"J Pharm Biomed Anal"},{"key":"2026021704061827800_ref18","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood.V112.11.2569.2569","article-title":"Complete responses in patients with autoimmune lymphoproliferative syndrome (ALPS) using the mTOR inhibitor sirolimus (rapamycin)","volume":"112","author":"Teachey","year":"2008","journal-title":"Blood"},{"key":"2026021704061827800_ref19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","article-title":"Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)","volume":"108","author":"Teachey","year":"2006","journal-title":"Blood"},{"key":"2026021704061827800_ref20","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"2026021704061827800_ref21","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jamadermatol.2021.3459","article-title":"Sirolimus (rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial","volume":"157","author":"Maruani","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026021704061827800_ref22","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.2217\/fon.13.141","article-title":"Mammalian target of rapamycin inhibitor-associated stomatitis","volume":"9","author":"Boers-Doets","year":"2013","journal-title":"Future Oncol"},{"key":"2026021704061827800_ref23","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/S2666-7568(23)00258-1","article-title":"Targeting ageing with rapamycin and its derivatives in humans: a systematic review","volume":"5","author":"Lee","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"2026021704061827800_ref24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ki.1996.28","article-title":"The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients","volume":"49","author":"Murgia","year":"1996","journal-title":"Kidney Int"},{"key":"2026021704061827800_ref25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1203\/00006450-200110000-00003","article-title":"The impact of corticosteroids on the developing animal","volume":"50","author":"Edwards","year":"2001","journal-title":"Pediatr Res"},{"key":"2026021704061827800_ref26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/hematology.2024000537","article-title":"Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase \u03b4 syndrome","volume":"2024","author":"Rao","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026021704061827800_ref27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40272-016-0175-3","article-title":"Optimal management of autoimmune lymphoproliferative syndrome in children","volume":"18","author":"George","year":"2016","journal-title":"Pediatric Drugs"},{"key":"2026021704061827800_ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fped.2015.00065","article-title":"Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome","volume":"3","author":"Rao","year":"2015","journal-title":"Front Pediatr"},{"key":"2026021704061827800_ref29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00007691-200410000-00001","article-title":"New insights into drug absorption: studies with sirolimus","volume":"26","author":"Paine","year":"2004","journal-title":"Ther Drug Monit"},{"key":"2026021704061827800_ref30","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1007\/s11357-025-01532-w","article-title":"The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals","volume":"47","author":"Harinath","year":"2025","journal-title":"GeroScience"},{"key":"2026021704061827800_ref31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/FTD.0000000000000130","article-title":"Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1","volume":"37","author":"Emoto","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2026021704061827800_ref32","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.12688\/f1000research.11545.1","article-title":"Autoimmune lymphoproliferative syndrome: more than a FAScinating disease","volume":"6","author":"Bride","year":"2017","journal-title":"F1000Res"},{"key":"2026021704061827800_ref33","doi-asserted-by":"publisher","first-page":"e000166","DOI":"10.1136\/vetreco-2015-000166","article-title":"Age-associated and breed-associated variations in haematological and biochemical variables in young labrador retriever and miniature schnauzer dogs","volume":"3","author":"Brenten","year":"2016","journal-title":"Vet Rec Open"},{"key":"2026021704061827800_ref34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/vec.12162","article-title":"Reference intervals and age-related changes for venous biochemical, hematological, electrolytic, and blood gas variables using a point of care analyzer in 68 puppies","volume":"24","author":"O\u2019Brien","year":"2014","journal-title":"J Vet Emerg Crit Care"},{"key":"2026021704061827800_ref35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/vcp.12220","article-title":"Age-related changes in hematologic and serum biochemical variables in dogs aged 16\u201360 days","volume":"44","author":"R\u00f8rtveit","year":"2015","journal-title":"Vet Clin Pathol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/1\/aalag010\/66937303\/aalag010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/1\/aalag010\/66937303\/aalag010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:06:22Z","timestamp":1771319182000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag010\/8487694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag010","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"aalag010"}}